MarketLens

What's Behind ARCH Venture Management's Reduced Stake in Maze Therapeutics

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Does BlackRock's Reduced Stake in Orion Corporation Signify

2 months ago

What's Driving the Surge in Analyst Confidence for Venture Global (VG)

4 months ago

What's Behind Acadian Asset Management's Recent Surge

4 months ago

What Does Senator Hagerty's Venture Capital Investment Signal

5 months ago

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Maze Therapeutics advanced MZE782 for PKU and MZE829 for APOL1 kidney disease; MZE782 showed best-in-class Phase 1 profile with Phase 2 set for mid-2026, while MZE829 posted strong uACR reductions but...

MAZE

Stock News•2 weeks ago

Assenagon Asset Management S.A. Sells 2,136,807 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Assenagon Asset Management cut its Ultragenyx Pharmaceutical stake 94.6% in Q3, selling 2,136,807 shares and leaving 120,864, per its 13F filing. The move signals reduced institutional conviction in t...

RARE

Stock News•1 months ago

A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.

Veracyte's chief accounting officer sold 24,000 shares for ~$1.1M at ~$45.40 each on May 22, reducing direct holdings by 34.57%.

VCYT

Breaking News

Event-Driven Investing

Healthcare

M&A

Robotics

Supply Chain Resilience

Top Headlines

View More →

Stock News•1 hour ago

Elon Musk Is Spending $119 Billion on A Single Building Outside Houston. Here's Who Actually Profits.

Stock News•2 hours ago

Dow Falls On News Of U.S.-Iran Attacks; Apple Slides

Stock News•2 hours ago

Amazon accused in new suit filed by FTC and 22 states of rigging ad auctions to inflate prices

Stock News•3 hours ago

You Could Buy Nvidia for Its 106% Revenue Growth and 75% Gross Margin. But There's an Even Better Reason the AI Stock Has Room to Run.

Stock News•3 hours ago

What's Behind ARCH Venture Management's Reduced Stake in Maze Therapeutics

Exclusive Content for Pro Members

Related Articles

What Does BlackRock's Reduced Stake in Orion Corporation Signify

What's Driving the Surge in Analyst Confidence for Venture Global (VG)

What's Behind Acadian Asset Management's Recent Surge

What Does Senator Hagerty's Venture Capital Investment Signal

Category

You may also like

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Assenagon Asset Management S.A. Sells 2,136,807 Shares of Ultragenyx Pharmaceutical Inc. $RARE

A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

Elon Musk Is Spending $119 Billion on A Single Building Outside Houston. Here's Who Actually Profits.

Dow Falls On News Of U.S.-Iran Attacks; Apple Slides

Amazon accused in new suit filed by FTC and 22 states of rigging ad auctions to inflate prices

You Could Buy Nvidia for Its 106% Revenue Growth and 75% Gross Margin. But There's an Even Better Reason the AI Stock Has Room to Run.

Tesla Stock Has Been on a Hot Streak Ahead of Big Event This Week